Docetaxel combined with cisplatin and vinorelbine combined with cisplatin treatment of 67 patients with advanced NSCLC.docVIP

 PAGE \* MERGEFORMAT 3 Docetaxel combined with cisplatin and vinorelbine combined with cisplatin treatment of 67 patients with advanced NSCLC [Abstract] [Objective] To compare docetaxel combined with cisplatin (DP) and vinorelbine combined with cisplatin (NP) first-line treatment of advanced non-small cell lung cancer (NSCLC) the efficacy and safety. [Method] 67 cases diagnosed by cytology or pathology of NSCLC patients were treated for DP (34 cases) or NP program (33 cases) chemotherapy were observed response rate (RR), time to progression (TTP), median survival time (MST) and 1 year, 2-year survival rate. [Results] DP group CR1 patients, PR14 cases, RR44.1%, TTP6.5 months, MST10.6 months, one year survival rate was 47.1%, 2-year survival rate was 23.5%. NP was no CR, PR10 cases, RR30.3%, TTP4.7 months, MST8.5 months. 1-year survival rate was 33.3%, 2-year survival rate was 12.1%. Tumor response rate difference between the two groups was statistically significant (P = 0.046). Adverse reactions similar to the two groups, no statistical significance. [Conclusion] docetaxel combined with cisplatin first-line treatment of advanced non-small cell lung cancer, tumor response rate is superior to vinorelbine combined with cisplatin, there is a better tolerance and higher clinical remission rate; but one year and two year survival rate difference was not significant. [Keywords:] cancer drug therapy Non-small cell lung cancer (NSCLC) about 80% of patients had already advanced when diagnosed, loss of surgical opportunities, combined with chemotherapy is the most important treatment, to a certain extent, prolong survival time of patients and improve the quality of life [1]. Third-generation chemotherapy drugs docetaxel and vinorelbine in NSCLC treatment appears to have more choices [2 ~ 4]. To compare the Docetaxel and vinorelbine in advanced NSCLS the role of oncology in our hospital from October 2001 to September 2003 using docetaxel combined with cisplatin (DP) and